Angiogenesis Inhibitors in NSCLC

Angiogenesis Inhibitors in NSCLC

Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with a...

Full description

Bibliographic Details
Main Authors: Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco, Alessandro Morabito
Format: Article
Language:English
Published: MDPI AG 2017-09-01
Series:International Journal of Molecular Sciences
Subjects:
angiogenesis
vascular endothelial growth factor (VEGF)
bevacizumab
nintedanib
ramucirumab
VEGF trap
Online Access:https://www.mdpi.com/1422-0067/18/10/2021

Internet

https://www.mdpi.com/1422-0067/18/10/2021

Similar Items